Annexin A7 AntibodyProduct information
|100 µl (10 western blots)||-||Unavailable in your region|
Product Pathways - Cytoskeletal Signaling
Annexin A7 Antibody #3666
|3666S||100 µl (10 western blots)||---||In Stock||---|
|3666||carrier free and custom formulation / quantity||email request|
|W||1:1000||Human, Monkey||Endogenous||47, 51||Rabbit|
Species cross-reactivity is determined by western blot.
Applications Key: W=Western Blotting
Specificity / Sensitivity
Annexin A7 Antibody detects endogenous levels of total annexin A7 protein, including isoforms 1 and 2.
Source / Purification
Polyclonal antibodies are produced by immunizing animals with a synthetic peptide corresponding to residues near the carboxy terminus of human annexin A7. Antibodies are purified using protein A and peptide affinity chromatography.
Annexin A7/ANXA7 is a member of the annexin family of calcium/phospholipid-binding proteins, and is involved in the process of membrane fusion and exocytosis (1). Annexin A7 is a GTPase, and both GTP-binding and PKC activity are important in regulating protein function (2,3). Membrane binding of annexin A7 is calcium dependent (4). Two isoforms exist due to alternative splicing. Subcellular localization of annexin A7 has been shown to be in the cytoplasm, vesicular structures, membrane and in adrenal chromaffin granules (5,6). Nuclear localization has been shown in the developing mouse central nervous system as well as in adult mouse brain (7). Annexin A7-deficient mouse studies show that the protein has a role in insulin secretion and calcium signaling (8) as well as cardiac intracellular calcium homeostasis electrical stability (9). The gene for annexin A7 is a putative tumor suppressor (10), and alterations in the copy number have been reported in prostate cancer (11). Annexin A7 expression has also been correlated with survival in human glioblastoma patients (12), and haploinsufficiency in mice may promote genetic instability leading to tumorigenesis (13).
- Pollard, H.B. et al. (1990) J Membr Biol 117, 101-12.
- Caohuy, H. and Pollard, H.B. (2002) J Biol Chem 277, 25217-25.
- Caohuy, H. et al. (1996) Proc Natl Acad Sci USA 93, 10797-802.
- Chander, A. et al. (2003) Cell Calcium 33, 11-7.
- Selbert, S. et al. (1995) J Cell Sci 108 ( Pt 1), 85-95.
- Clemen, C.S. et al. (2001) Neuroreport 12, 1139-44.
- Rick, M. et al. (2005) BMC Neurosci 6, 25.
- Srivastava, M. et al. (1999) Proc Natl Acad Sci USA 96, 13783-8.
- Schrickel, J.W. et al. (2007) Cardiovasc Res 76, 257-68.
- Srivastava, M. et al. (2001) Proc Natl Acad Sci USA 98, 4575-80.
- Dong, J.T. (2006) J Cell Biochem 97, 433-47.
- Hung, K.S. and Howng, S.L. (2003) J Neurosurg 99, 886-92.
- Srivastava, M. et al. (2003) Proc Natl Acad Sci USA 100, 14287-92.
Have you published research involving the use of our products? If so we'd love to hear about it. Please let us know!
This product is intended for research purposes only. The product is not intended to be used for therapeutic or diagnostic purposes in humans or animals.
Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.
The Annexin V-FITC conjugate is a product manufactured for Cell Signaling Technology, Inc. by TAU Technologies BV.